NASDAQ$MLTX
MoonLake Immunotherapeutics · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Reports in 3 weeks
MoonLake hasn't published Q2 2025 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.
Most recent report Q4 2026
- Revenue
- —
- EPS
- -$3.03
Year-ago · Q2 2024 Q2 2024
- Revenue
- —
- EPS
- —
FY2025 consensus Analyst consensus
- Revenue
- $0.00
- EPS
- -$3.07
Revenue & EPS history
MoonLake · Revenue · Quarterly
$350M
Q3 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.7%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+23.1%
Q2 2022
Best reaction
-10.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.2% | -2.9% | -4.8% | |
| Q3 2025 | -2.8% | +11.0% | +40.7% | |
| Q1 2025 | +4.7% | -2.2% | +14.8% | |
| Q4 2024 | -4.5% | -2.5% | -2.1% | |
| Q3 2024 | +0.6% | +0.8% | +5.5% | |
| Q1 2024 | -4.2% | -8.1% | -4.7% | |
| Q4 2023 | -10.4% | -15.3% | -11.6% | |
| Q3 2023 | +7.1% | +16.6% | +57.3% | |
| Q2 2023 | +3.5% | +3.8% | -5.7% | |
| Q1 2023 | +0.2% | +5.5% | +9.6% | |
| Q4 2022 | -4.9% | -9.2% | -5.6% | |
| Q3 2022 | -0.1% | -5.4% | +4.0% | |
| Q2 2022 | +23.1% | +45.8% | +33.0% | |
| Q1 2022 | -6.1% | +4.3% | +2.6% | |
| Q2 2021 | -0.1% | +0.0% | -0.1% | |
| Q4 2021 | -0.1% | +0.0% | -0.1% | |
| Q3 2021 | -1.3% | -1.3% | -1.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro